TransMedics Group, Inc. (NASDAQ:TMDX – Get Free Report) has received a consensus rating of “Moderate Buy” from the eleven research firms that are presently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $122.70.
Several brokerages have issued reports on TMDX. Canaccord Genuity Group reissued a “buy” rating and issued a $104.00 price target on shares of TransMedics Group in a report on Tuesday, March 11th. Oppenheimer reissued an “outperform” rating and issued a $125.00 price target on shares of TransMedics Group in a report on Tuesday, December 3rd. Piper Sandler lowered their price target on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a report on Wednesday, December 11th. TD Cowen lowered their price target on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a report on Monday, November 18th. Finally, Robert W. Baird lowered their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th.
Get Our Latest Report on TransMedics Group
TransMedics Group Trading Up 6.5 %
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Atlas Capital Advisors Inc. acquired a new position in TransMedics Group during the 4th quarter worth about $31,000. Hager Investment Management Services LLC acquired a new position in TransMedics Group during the 4th quarter worth about $33,000. Sachetta LLC acquired a new position in TransMedics Group during the 4th quarter worth about $40,000. AlphaQuest LLC acquired a new position in TransMedics Group during the 4th quarter worth about $52,000. Finally, Quarry LP raised its holdings in TransMedics Group by 557.1% during the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after purchasing an additional 312 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.
TransMedics Group Company Profile
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
See Also
- Five stocks we like better than TransMedics Group
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.